Document Detail


Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
MedLine Citation:
PMID:  16246656     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Mifepristone-misoprostol medical abortion has been approved in the United States since 2000. U.S. providers have preferred to use vaginal misoprostol because of evidence that such a regimen is more effective in later gestations. Buccal administration of misoprostol may be equally effective and more acceptable to some women. METHODS: This open-label, randomized trial was conducted at two sites in Rochester, NY, and involved healthy women with pregnancies through 56 days since the last menstrual period (LMP) as indicated by sonogram. Women received mifepristone 200 mg orally and were randomized to use 800 mug of misoprostol either buccally or vaginally 1 to 2 days later. They returned within 15 days for repeat sonogram. If the woman's pregnancy had not been completely aborted by day 36, a suction abortion was performed. The primary outcome was a complete abortion without surgical intervention. RESULTS: Four hundred forty-two women were enrolled in the study, and complete data were available on 429. The efficacy rate was 95% (205/216) in the buccal group and 93% (199/213) in the vaginal group (chi(2)=0.43, p=.51). Nausea was the most commonly reported side effect, affecting 70% in the buccal group and 62% in the vaginal group. There were no differences in the satisfaction with the overall procedure between the buccal (92%) and the vaginal groups (95%) (chi(2)=1.87, p=.17). CONCLUSION: Buccal administration of misoprostol after low-dose mifepristone for medical abortion appears to be a highly effective and acceptable alternative compared with vaginal administration for medical abortion in pregnancies through 56 days LMP.
Authors:
Tamer Middleton; Eric Schaff; Stephen L Fielding; Mary Scahill; Caitlin Shannon; Emily Westheimer; Tracey Wilkinson; Beverly Winikoff
Related Documents :
16781256 - The pharmacokinetics and different regimens of misoprostol in early first-trimester med...
4143606 - Legal abortion: a critical assessment of its risks.
17320086 - Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus.
15057956 - Prenatal diagnosis and management of sex chromosome aneuploidy: a report on 98 cases.
19541246 - Changing behavioral risk for pregnancy among high school students in the united states,...
7073336 - Effect of sulprostone on concentrations of progesterone, 20 alpha-dihydroprogesterone, ...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2005-08-09
Journal Detail:
Title:  Contraception     Volume:  72     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-25     Completed Date:  2007-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  328-32     Citation Subset:  IM    
Affiliation:
Department of Family Medicine, University of Rochester School of Medicine, Rochester, NY 14620, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal / administration & dosage*
Abortifacient Agents, Steroidal / administration & dosage*
Abortion, Induced*
Administration, Buccal
Administration, Intravaginal
Adolescent
Adult
Chi-Square Distribution
Female
Gestational Age
Humans
Middle Aged
Mifepristone / administration & dosage*
Misoprostol / administration & dosage*
Pregnancy
Pregnancy Outcome
Prospective Studies
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Abortifacient Agents, Steroidal; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral...
Next Document:  Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditi...